Kiniksa Pharmaceuticals

Historical price data

Kiniksa Pharmaceuticals is a publicly traded biopharma focused on immune modulation for cardiovascular and autoimmune diseases with high unmet need. Founded in 2015, its key achievement is the FDA approval and commercialization of ARCALYST® (rilonacept), the first and only therapy for recurrent pericarditis, providing a foundational revenue stream. The company's strategy leverages strategic in-licensing and targeted development of biologics with strong biologic rationale, building a balanced portfolio that spans commercial and clinical-stage assets. This approach, led by a seasoned team with a proven track record in rare diseases, aims to deliver differentiated therapies rapidly.

Kiniksa employs an indication-driven strategic platform focused on in-licensing and developing immune-modulating biologics that target validated pathways (e.g., IL-1, GM-CSF, CD40) for serious diseases with high unmet need, rather than a single proprietary discovery technology.

In recurrent pericarditis, ARCALYST is first-in-class with no direct approved competitors, competing against generic standard-of-care. In rheumatoid arthritis, KPL-404 will enter a crowded market dominated by multiple drug classes and must differentiate on mechanism. In rare cardiovascular diseases, competition is nascent but growing as immunology gains traction in cardiology.